Bona fide gift to Reed Tuckson of 43785 shares of CTi Biopharma subject to Section 16

CTICDelisted Stock  USD 9.09  0.00  0.00%   
About 56% of CTi Biopharma's investor base is looking to short. The analysis of current outlook of investing in CTi Biopharma Corp suggests that many traders are alarmed regarding CTi Biopharma's prospects. The current market sentiment, together with CTi Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use CTi Biopharma Corp stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Cti Biopharma Corp director. Exempt bona fide gift subject to Rule 16b-3

Read at macroaxis.com
CTi Biopharma insider trading alert for gift of common stock by Reed Tuckson, the corporate stakeholder, on 14th of February 2023. This event was filed by Cti Biopharma Corp with SEC on 2023-02-14. Annual statement of changes in beneficial ownership - SEC Form 5

CTi Biopharma Fundamental Analysis

We analyze CTi Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CTi Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CTi Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Profit Margin

Profit Margin Comparative Analysis

CTi Biopharma is currently under evaluation in profit margin category among its peers. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

CTi Biopharma Corp Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with CTi Biopharma stock to make a market-neutral strategy. Peer analysis of CTi Biopharma could also be used in its relative valuation, which is a method of valuing CTi Biopharma by comparing valuation metrics with similar companies.

Peers

CTi Biopharma Related Equities

ELEVElevation Oncology   10.00   
0%
100.0%
IBRXImmunitybio   9.34   
0%
93.0%
MCRBSeres Therapeutics   8.33   
0%
83.0%
VSTMVerastem   7.86   
0%
78.0%
PLXProtalix Biotherapeutics   7.61   
0%
76.0%
CRVSCorvus Pharmaceuticals   7.37   
0%
73.0%
FBIOFortress Biotech   5.19   
0%
51.0%
VKTXViking Therapeutics   4.30   
0%
43.0%
PDSBPDS Biotechnology   4.05   
0%
40.0%
MDGLMadrigal Pharmaceuticals   1.88   
0%
18.0%
RIGLRigel Pharmaceuticals   0.35   
0%
3.0%
XFORX4 Pharmaceuticals   1.33   
13.0%
0%
IMMPImmutep   1.36   
13.0%
0%
CDTXCidara Therapeutics   2.49   
24.0%
0%
TGTXTG Therapeutics   3.25   
32.0%
0%
RVPHReviva Pharmaceuticals   5.47   
54.0%
0%
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Consideration for investing in CTi Stock

If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes